1IJ Stock Chart & Stats
€7.20
-€0.30(-4.00%)
At close: 4:00 PM EDT
€7.20
-€0.30(-4.00%)
Day’s Range― - ―
52-Week Range€5.05 - €15.00
Previous CloseN/A
Volume350.00
Average Volume (3M)78.00
Market Cap
€73.61M
Enterprise Value-€12.49
Total Cash (Recent Filing)€118.19M
Total Debt (Recent Filing)€12.85M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Nov 11, 2026EPS Estimate
-1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.45
Shares Outstanding9,361,490
10 Day Avg. Volume235
30 Day Avg. Volume78
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€19.25Price Target Upside167.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-6.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageLow leverage limits interest and refinancing pressure, giving Adicet greater financial flexibility than a similarly loss-making biotech. This provides some balance-sheet resilience while the company funds clinical development and seeks future commercial progress.
Losses Have NarrowedThe reduction in net losses suggests some improvement in cost control or development efficiency over time. Although profitability remains distant, sustained loss improvement could extend the runway and improve operating leverage if pipeline investment continues to mature.
Off-the-Shelf Cell Therapy PlatformAn allogeneic, off-the-shelf approach could offer manufacturing and administration advantages over patient-specific therapies if clinical benefits are demonstrated. Standardized products may support broader scalability and more predictable delivery across cancer treatment settings.
Bears Say
No Meaningful Commercial RevenueThe absence of meaningful revenue shows that Adicet remains dependent on clinical development rather than commercial operations. Until a candidate is approved and adopted, the company lacks recurring product sales to fund research, overhead, and future expansion.
Persistent Cash BurnLarge recurring cash outflows require continued access to external capital while clinical programs advance. This dependence can constrain development choices and create dilution or financing risk if internal resources do not improve before major products generate revenue.
Shrinking Equity BaseThe substantial reduction in equity reflects prolonged losses and erosion of the capital base. Combined with sharply negative returns on equity, this indicates that shareholder resources are being consumed without current earnings support, increasing long-term funding pressure.
Adicet Bio News
1IJ FAQ
What was Adicet Bio’s price range in the past 12 months?
Adicet Bio lowest stock price was €5.05 and its highest was €15.00 in the past 12 months.
What is Adicet Bio’s market cap?
Adicet Bio’s market cap is €73.61M.
When is Adicet Bio’s upcoming earnings report date?
Adicet Bio’s upcoming earnings report date is Nov 11, 2026 which is in 80 days.
How were Adicet Bio’s earnings last quarter?
Adicet Bio released its earnings results on Aug 05, 2026. The company reported -€1.724 earnings per share for the quarter, missing the consensus estimate of -€1.465 by -€0.258.
Is Adicet Bio overvalued?
According to Wall Street analysts Adicet Bio’s price is currently Undervalued.
Does Adicet Bio pay dividends?
Adicet Bio does not currently pay dividends.
What is Adicet Bio’s EPS estimate?
Adicet Bio’s EPS estimate is -1.2.
How many shares outstanding does Adicet Bio have?
Adicet Bio has 9,361,490 shares outstanding.
What happened to Adicet Bio’s price movement after its last earnings report?
Adicet Bio reported an EPS of -€1.724 in its last earnings report, missing expectations of -€1.465. Following the earnings report the stock price went down -21.212%.
Which hedge fund is a major shareholder of Adicet Bio?
Currently, no hedge funds are holding shares in DE:1IJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adicet Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€19.25 (167.38% Upside)
€19.25 (167.38% Upside)
Blogger Sentiment
Bullish
DE:1IJ Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-37.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.08%
Trailing 12-Months
Company Description
Adicet Bio
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
1IJ Stock 12 Month Forecast
Average Price Target
€19.25
▲(167.38% Upside)